medigraphic.com

2006, Number 1

<< Back Next >>

Arch Cardiol Mex 2006; 76 (1)

“Cardiac Power Output” an old tool, possibly a modern tool for assessing cardiac pumping capability, as well as for a short-term prognosis in cardiogenic shock due to acute myocardial infarction

Lupi HE, Chuquiure VE, González PH, Cuéllar VBM, Arias MA, Martínez SCR

Language: Spanish
References: 41
Page: 95-108
PDF size: 126.18 Kb.


ABSTRACT

Hemodynamic monitoring has been used extensively during the last decades for risk stratification and guiding treatment of patients with cardiovascular destabilization, especially in the scenario of acute heart failure and cardiac shock. Every cardiac pump has its own maximum performance, which denotes its pumping capability. The heart is a muscular mechanical pump with an ability to generate both flow (cardiac output) and pressure. The product of flow output and systemic arterial pressure is the rate of useful work done, “or the cardiac power” (CP). Cardiac pumping capability can be defined as the cardiac power output achieved by the heart during maximal stimulation, and cardiac reserve is the increase in power output as the cardiac performance is increased from the resting to the maximally stimulated state (CPR). Resting CP for a hemodynamically stable average sized adult is approximately 1 W. However, during stress or exercise, CPR can be ecruited to increase the heart´s pumping ability up to 6 W. In acute heart failure, the patient becomes hemodynamically unstable, and most of the cardiac pumping potential is recruited in order to sustain life. Hence, cardiac power measurements in patients with acute heart failure or with cardiogenic shock at rest represent most of the recruitable reserve available during the acute event, and their measurement reflects the severity of the patient’s condition. It has been found that a cutoff value for CP of 0.53 W accurately predict in-hospital mortality for cardiogenic shock patients. Others investigators observed cutoff for increased mortality of CP ‹ 1 W, data that were obtained at doses of maximal pharmacologic support yielding the individual maximal CP. In our experience, the cutoff value for CP that accurately predicts in-hospital mortality for cardiogenic shock patients is 0.7 W, but its impact on short-term prognosis is clearer if the patient achieves a CP equal or higher than 1 W after an optimal myocardial revascularization with interventional cardiac procedures. According to the data collected from the literature, CP deserves a place in the evaluation of the patient with cardiogenic shock due to an acute myocardial infarction, but a more profound analysis of this parameter an further evaluation are required in order to better understand its prognostic meaning in this acute cardiac syndrome.


REFERENCES

  1. CHATTERJEE K: Vasodilator therapy for heart failure. Ann Intern Med 1975; 83: 421-423.

  2. CHATTERJEE K, PARMLEY WW: The role of vasodilator therapy in heart failure. Prog Cardiovasc Dis 1976; 19: 301-325.

  3. COHN JN, FRANCIOSA JA: Vasodilator therapy of cardiac failure. N Engl J Med 1977; 297: 27-31.

  4. FRANCIOSA JA, PIERPONT G, COHN JN: Hemodynamic improvement after oral hydralazine in left ventricular failure. Ann Intern Med 1977; 86: 388-393.

  5. CHATTERJEE K, DREW D, PARMLEY WW, KLAUSNER SC, POLANSKY J, ZACHERIE B: Combination vasodilator therapy for severe chronic heart failure. Ann Intern Med 1976; 85: 467-470.

  6. ZELIS R, FLAIM SF: Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc Dis 1982; 24: 437-459.

  7. MASON DT, ZELIS R, LONGHURST J, LEE G: Cardiocirculatory responses to muscular exercise in congestive heart failure. Prog Cardiovasc Dis 1977; 19: 475-489.

  8. TAN LB: Clinical and research implications of new concepts in the assessment of cardiac pumping performance in heart failure. Cardiovasc Res 1987; 21: 615-622.

  9. BENGE W, LITCHFIELD RL, MARCUS ML: Exercise capacity in patients with severe left ventricular dysfunction. Circulation 1980; 60: 955-959.

  10. FRANCIOSA JA, PARK M, LEVINE TB: Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol 1981; 47: 33-39.

  11. TAN LB: Cardiac pumping capability and prognosis in heart failure. Lancet 1987; ii: 1360-1363.

  12. BERGEL DH, CLARK C, SCHULTZ DL, TUNSTALL-PEDOE DS: The determination of the mechanical energy expenditure during ventricular pumping. J Physiol 1969; 204: 70-71P.

  13. HOLZER J, KARLINER JS, O´ROURKE RA, PITT W, ROSS J: Effectiveness of dopamine in patients with cardiogenic shock. Am J Cardiol 1973; 32: 79-84.

  14. GOLDBERG LI, HSIEH YY, RESNEKOV L: Newer catecholamines for treatment of heart failure and shock: an update on dopamine and first look at dobutamine. Prog Cardiovasc Dis 1977; 19: 327-340.

  15. RICHARD C, RICOME JL, RIMAILHO A, BOTTINEAU G, AUZEPY P: Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation 1983; 67: 620-626.

  16. MOYER J, SKELTON J, MILLIS L: Norepinephrine: effect in normal subjects; use in treatment of shock unresponsive to other measures. Am J Med 1953; 15: 330-343.

  17. HOLLENBERG SM, PARRILLO JE: Pharmacologic Circulatory Support. En: Shires GT, Barie PL (Eds): Surgical Critical Care. New York: Little, Brown; 1993: 417-451.

  18. TAN LB, LITTLER WA: Measurement of cardiac reserve in cardiogenic shock: implications for prognosis and management. Br Heart J 1990; 64: 121-128.

  19. STACK RS, CALIFF RM, HINOHARA T, PHILLIPS HR, PRYOR DB, SIMONTON CA, ET AL: Survival and cardiac event rate in the first year after emergency coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1988; 11: 1141-1149.

  20. GROSSMAN W: Evaluation of systolic and diastolic function of the myocardium. En: Grossman W, Ed. Cardiac Catheterization and angiography, 3rd ed. Philadelphia: Lea and Febiger 1983: 301-319.

  21. COLUCCI WS, RIBERO JP, ROCCO MB, QUIGG RJ, CREAGER MA, MARSH JD, ET AL: Impaired chronotropic response to exercise in patients with congestive heart failure. Role of postsynaptic B-adrenergic desensitization. Circulation 1989; 80: 314-323.

  22. COTTER G, WILLIAMS SG, VERED Z, TAN LB: Role of cardiac power in heart failure. Curr Opin Cardiol 2003; 18: 215-222.

  23. COTTER G, MOSHKOVITZ Y, MILOVANOV O, SALAH A, BLATT A, KRAKOVER R, ET AL: Acute congestive heart failure: A novel approach to its pathogenesis and treatment. Eur J Heart Fail 2002; 4: 227-234.

  24. FINCKE R, HOCHMAN JS, LOWE AM, MENON V, SLATER JN, WEBB JG, ET AL for the SHOCK Investigators: Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK Trial Registry. J Am Coll Cardiol 2004; 44: 340-348.

  25. CONNORS AF, SPEROFF T, DAWSON NV, THOMAS C, HARRELL FE, WAGNER D, ET AL for the SUPPORT Investigators: The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996; 276: 889-897.

  26. PICARD MH, DAVIDOFF R, SLEEPER L, MENDES LA, THOMPSON CR, DZAVIK V, ET AL for the Shock Trial: Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 2003; 107: 279-284.

  27. HASDAI D, HOLMES DR, CALIFF RM, THOMPSON TD, HOCHMAN JS, PFISTERER M, TOPOL EJ, Gusto-I Investigators: Cardiogenic shock complicating acute myocardial infarction: predictors of death. Am Heart J 1999; 138: 21-31.

  28. HAAS GJ, YOUNG JB: Acute heart failure management. En: Topol EJ, Ed. Textbook of Cardiovascular Medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2002: 1856-1858.

  29. CONWAY J, WHEELER R, SANNERSTEDT R: Sympathetic nervous activity during exercise in relation to age. Cardiovasc Res 1971; 5: 577-581.

  30. JULIUS S, ANTOON A, WHITLOCK LS, CONWAY J: Influence of age on the hemodynamic response to exercise. Circulation 1967; 36: 222-226.

  31. LAKATTA EG, LEVY D: Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Circulation 2003; 107: 346-354.

  32. COTTER G, MOSHKOWITZ Y, KALUSKI E, COHEN AJ, MILLER H, GOOR D, VERED Z: Accurate noninvasive continuous monitoring of cardiac output by whole body electrical bio-impedance. Chest 2004; 125: 1431-1440.

  33. OLIVETTI G, MELISSARI M, CAPASSO JM, ANVERSA P: Cardiomyopathy of the aging human heart. Circ Res 1991; 68: 1560-1568.

  34. GOLDSPINK DF, BURNISTON JG, TAN LB: Cardiomyocyte death and the aging and failing heart. Exp Physiol 2003; 88: 447- 458.

  35. HOCHMAN JS: Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003; 107: 2998-3002.

  36. HOLLENBERG SM, KAVINSKY CJ, PARRILLO JE: Cardiogenic shock. Ann Intern Med 1999; 131: 47-49.

  37. WONG SC, SANBORN T, SLEEPER LA, WEBB JG, PILCHIK R, HART D, ET AL for the Shock Investigators: Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: A report from the Shock trial registry. J Am Coll Cardiol 2000; 36: 1077-1083.

  38. LUPI HE, GONZÁLEZ PH, JUÁREZ UH, CHUQUIURE E, VIEYRA G, MARTÍNEZ SC: La meta de la reperfusión en los síndromes isquémicos coronarios agudos con elevación del segmento ST. «Lo que hay más allá del flujo TIMI 3 epicárdico». Arch Cardiol Mex 2002; 72: 311-349.

  39. CUELLAR BMV: Poder cardíaco como factor pronóstico de sobrevida en pacientes con infarto agudo del miocardio complicado con choque cardiogénico. Tesis de postgrado. División de Estudios de Postgrado Facultad de Medicina. Universidad Nacional Autónoma de México. México, DF. 2005.

  40. KOHSAKA S, MENON V, LOWE AM, LANGE M, DZAVIK V, SLEEPER LA, HOCHMAN JS, for the SHOCK Investigators: Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005; 165: 1643-1650.

  41. LUPI HE, LASSES LA, COSIO AJ, CHUQUIURE EV, MARTÍNEZ SC, ORTÍZ P, ET AL: Acute right ventricular infarction: clinical spectrum, results of reperfusion therapy and short-term prognosis. Cor Artery Dis 2002; 13: 57-64.




2020     |     www.medigraphic.com